Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

The effect of different antidepressant drugs on oxidative stress after lipopolysaccharide administration in mice.

Abdel-Salam OME, Morsy SMY, Sleem AA.

EXCLI J. 2011 Dec 8;10:290-302. eCollection 2011.

2.

Effect of treatments for depression on quality of life: a meta-analysis.

Hofmann SG, Curtiss J, Carpenter JK, Kind S.

Cogn Behav Ther. 2017 Jun;46(4):265-286. doi: 10.1080/16506073.2017.1304445. Epub 2017 Apr 25.

PMID:
28440699
3.

Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity.

Telles-Correia D, Barbosa A, Cortez-Pinto H, Campos C, Rocha NB, Machado S.

World J Gastrointest Pharmacol Ther. 2017 Feb 6;8(1):26-38. doi: 10.4292/wjgpt.v8.i1.26. Review.

4.

Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications.

Hauser P, Kern S.

World J Hepatol. 2015 Jul 28;7(15):1921-35. doi: 10.4254/wjh.v7.i15.1921. Review.

5.

Psychosocial issues in patients with chronic hepatitis B and C.

Enescu A, Mitrut P, Balasoiu M, Turculeanu A, Enescu AS.

Curr Health Sci J. 2014 Apr-Jun;40(2):93-6. doi: 10.12865/CHSJ.40.02.02. Epub 2014 Mar 29. Review.

6.
7.

Psychiatric treatment considerations with direct acting antivirals in hepatitis C.

Sockalingam S, Tseng A, Giguere P, Wong D.

BMC Gastroenterol. 2013 May 14;13:86. doi: 10.1186/1471-230X-13-86. Review.

8.

Psychiatric care of the patient with hepatitis C: a review of the literature.

Rifai MA, Gleason OC, Sabouni D.

Prim Care Companion J Clin Psychiatry. 2010;12(6). pii: PCC.09r00877. doi: 10.4088/PCC.09r00877whi.

9.

No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C.

Kronfol Z, Litman HJ, Back-Madruga C, Bieliauskas LA, Lindsay KL, Lok AS, Fontana RJ; HALT-C Trial Group.

J Affect Disord. 2011 Mar;129(1-3):205-12. doi: 10.1016/j.jad.2010.09.010.

10.
11.
12.

Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C.

Fontana RJ, Kronfol Z, Lindsay KL, Bieliauskas LA, Padmanabhan L, Back-Madruga C, Lok AS, Stoddard AM; HALT-C Trial Group.

Am J Gastroenterol. 2008 Nov;103(11):2766-75. doi: 10.1111/j.1572-0241.2008.02106.x. Epub 2008 Aug 21.

13.

Depression and cigarette smoking independently relate to reduced health-related quality of life among Canadians living with hepatitis C.

Balfour L, Cooper C, Kowal J, Tasca GA, Silverman A, Kane M, Garber G.

Can J Gastroenterol. 2006 Feb;20(2):81-6.

14.

Major depressive disorder in hepatitis C: an open-label trial of escitalopram.

Gleason OC, Yates WR, Philipsen MA.

Prim Care Companion J Clin Psychiatry. 2005;7(5):225-30.

15.

Neuropsychiatric adverse effects of interferon-alpha: recognition and management.

Raison CL, Demetrashvili M, Capuron L, Miller AH.

CNS Drugs. 2005;19(2):105-23. Review.

16.

Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory.

Golub ET, Latka M, Hagan H, Havens JR, Hudson SM, Kapadia F, Campbell JV, Garfein RS, Thomas DL, Strathdee SA; STRIVE Project.

J Urban Health. 2004 Jun;81(2):278-90.

17.

Racial differences in hepatitis B and hepatitis C and associated risk behaviors in veterans with severe mental illness.

Butterfield MI, Bosworth HB, Stechuchak KM, Frothingham R, Bastian LA, Meador KG, Swartz M, Horner RD.

J Natl Med Assoc. 2004 Jan;96(1):43-52.

Supplemental Content

Support Center